In 2015 American Thyroid Association (ATA) guideline on the management of thyroid nodule and thyroid cancer, the change of Tg to therapy has been adopted as one of the essential parts in response to therapy system[2], while little study has focused on predictive performance of quantitative Tg response in RAIR-DTC so far. The gene discussed is TG; the disease is thyroid gland carcinoma.